Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback